ReviewBrain pathology (Zurich, Switzerland)2022
Embryonal and non-meningothelial mesenchymal tumors of the central nervous system - Advances in diagnosis and prognostication.
Review in Brain pathology (Zurich, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Non-Meningothelial Mesenchymal Tumor of the Central Nervous System: Case Report and Literature Review.Neuropathology : official journal of the Japanese Society of Neuropathology · 2026Review
- Mesenchymal Nonmeningothelial Tumors of the CNS: Evolving Molecular Landscape and Implications for Neuroradiologists.AJNR. American journal of neuroradiology · 2025Review
- Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level.Nature communications · 2024Article
- Central nervous system tumors of uncertain differentiation.World neurosurgery: X · 2024Review
- Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Frontiers in molecular neuroscience · 2024Review
- Intracranial mesenchymal tumor with (novel) COX14::PTEN rearrangement.Acta neuropathologica communications · 2023Article
- Clinicopathological and molecular characterization of a case classified by DNA‑methylation profiling as "CNS embryonal tumor with BRD4-LEUTX fusion".Acta neuropathologica communications · 2023Article
- Embryonal and non-meningothelial mesenchymal tumors of the central nervous system - Advances in diagnosis and prognostication.Brain pathology (Zurich, Switzerland) · 2022Review
- The WHO classification of tumors of the central nervous system-finally here, and welcome!Brain pathology (Zurich, Switzerland) · 2022Article
- Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.Molecules (Basel, Switzerland) · 2022Review
- A human embryonic stem cell-based model reveals the cell of origin of FOXR2-activated CNS neuroblastoma.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5th edition of the WHO Classification of Tumours of the Central Nervous System introduces new entities, and provides updated guidance regarding the diagnostic criteria for tumors of the central nervous system (CNS). CNS embryonal tumors and CNS non-meningothelial mesenchymal tumors can be challenging for practicing pathologists, as the histologic features are not always specific to a particular entity, and integration of microscopic and molecular findings is necessary. This review on CNS embryonal and non-meningothelial mesenchymal tumors is meant to provide an update with a focus on WHO changes and additions and on recent discoveries with diagnostic, prognostic, and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.